169 related articles for article (PubMed ID: 20038807)
1. Putting the brakes on BTLA in T cell-mediated cancer immunotherapy.
Paulos CM; June CH
J Clin Invest; 2010 Jan; 120(1):76-80. PubMed ID: 20038807
[TBL] [Abstract][Full Text] [Related]
2. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination.
Derré L; Rivals JP; Jandus C; Pastor S; Rimoldi D; Romero P; Michielin O; Olive D; Speiser DE
J Clin Invest; 2010 Jan; 120(1):157-67. PubMed ID: 20038811
[TBL] [Abstract][Full Text] [Related]
3. B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation.
Hobo W; Norde WJ; Schaap N; Fredrix H; Maas F; Schellens K; Falkenburg JH; Korman AJ; Olive D; van der Voort R; Dolstra H
J Immunol; 2012 Jul; 189(1):39-49. PubMed ID: 22634623
[TBL] [Abstract][Full Text] [Related]
4. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1.
Watanabe N; Gavrieli M; Sedy JR; Yang J; Fallarino F; Loftin SK; Hurchla MA; Zimmerman N; Sim J; Zang X; Murphy TL; Russell JH; Allison JP; Murphy KM
Nat Immunol; 2003 Jul; 4(7):670-9. PubMed ID: 12796776
[TBL] [Abstract][Full Text] [Related]
5. Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients.
Karabon L; Partyka A; Ciszak L; Pawlak-Adamska E; Tomkiewicz A; Bojarska-Junak A; Roliński J; Wołowiec D; Wrobel T; Frydecka I; Kosmaczewska A
J Immunol Res; 2020; 2020():6545921. PubMed ID: 32775467
[TBL] [Abstract][Full Text] [Related]
6. Distinct expression and inhibitory function of B and T lymphocyte attenuator on human T cells.
Wang XF; Chen YJ; Wang Q; Ge Y; Dai Q; Yang KF; Fang-Xie ; Zhou YH; Hu YM; Mao YX; Zhang XG
Tissue Antigens; 2007 Feb; 69(2):145-53. PubMed ID: 17257317
[TBL] [Abstract][Full Text] [Related]
7. B and T lymphocyte attenuator is highly expressed on CMV-specific T cells during infection and regulates their function.
Serriari NE; Gondois-Rey F; Guillaume Y; Remmerswaal EB; Pastor S; Messal N; Truneh A; Hirsch I; van Lier RA; Olive D
J Immunol; 2010 Sep; 185(6):3140-8. PubMed ID: 20693422
[TBL] [Abstract][Full Text] [Related]
8. CpG-ODN-induced sustained expression of BTLA mediating selective inhibition of human B cells.
Thibult ML; Rivals JP; Mamessier E; Gertner-Dardenne J; Pastor S; Speiser DE; Derré L; Olive D
J Mol Med (Berl); 2013 Feb; 91(2):195-205. PubMed ID: 22903545
[TBL] [Abstract][Full Text] [Related]
9. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.
Cai G; Freeman GJ
Immunol Rev; 2009 May; 229(1):244-58. PubMed ID: 19426226
[TBL] [Abstract][Full Text] [Related]
10. Expression and function of the B and T lymphocyte attenuator (BTLA/CD272) on human T cells.
Otsuki N; Kamimura Y; Hashiguchi M; Azuma M
Biochem Biophys Res Commun; 2006 Jun; 344(4):1121-7. PubMed ID: 16643847
[TBL] [Abstract][Full Text] [Related]
11. Multifaceted Role of BTLA in the Control of CD8
Ritthipichai K; Haymaker CL; Martinez M; Aschenbrenner A; Yi X; Zhang M; Kale C; Vence LM; Roszik J; Hailemichael Y; Overwijk WW; Varadarajan N; Nurieva R; Radvanyi LG; Hwu P; Bernatchez C
Clin Cancer Res; 2017 Oct; 23(20):6151-6164. PubMed ID: 28754817
[No Abstract] [Full Text] [Related]
12. Ligation of B and T lymphocyte attenuator prevents the genesis of experimental cerebral malaria.
Lepenies B; Pfeffer K; Hurchla MA; Murphy TL; Murphy KM; Oetzel J; Fleischer B; Jacobs T
J Immunol; 2007 Sep; 179(6):4093-100. PubMed ID: 17785848
[TBL] [Abstract][Full Text] [Related]
13. Role of B and T Lymphocyte Attenuator in Renal Transplant Recipients with Biopsy-Proven Acute Rejection.
Wang Z; Yang H; Liu X; Zhang J; Han Z; Tao J; Zhao C; Ju X; Tan R; Gu M
Med Sci Monit; 2018 Jan; 24():387-396. PubMed ID: 29352109
[TBL] [Abstract][Full Text] [Related]
14. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator.
Gonzalez LC; Loyet KM; Calemine-Fenaux J; Chauhan V; Wranik B; Ouyang W; Eaton DL
Proc Natl Acad Sci U S A; 2005 Jan; 102(4):1116-21. PubMed ID: 15647361
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT.
Kojima R; Kajikawa M; Shiroishi M; Kuroki K; Maenaka K
J Mol Biol; 2011 Nov; 413(4):762-72. PubMed ID: 21959263
[TBL] [Abstract][Full Text] [Related]
16. Genetic signature of CTLA-4, BTLA, TIM-3 and LAG-3 molecular expression in colorectal cancer patients: Implications in diagnosis and survival outcomes.
Kamal AM; Wasfey EF; Elghamry WR; Sabry OM; Elghobary HA; Radwan SM
Clin Biochem; 2021 Oct; 96():13-18. PubMed ID: 34217699
[TBL] [Abstract][Full Text] [Related]
17. BTLA: a new inhibitory receptor with a B7-like ligand.
Carreno BM; Collins M
Trends Immunol; 2003 Oct; 24(10):524-7. PubMed ID: 14552835
[TBL] [Abstract][Full Text] [Related]
18. Hepatic expansion of virus-specific CD8
Wang H; Wu B; Li L; Hu L; Lin J; Jiang C; Cai G; Shen Q
Cell Immunol; 2017 Jan; 311():36-45. PubMed ID: 27743606
[TBL] [Abstract][Full Text] [Related]
19. Age-related changes in the gene expression profile of antigen-specific mouse CD8+ T cells can be partially reversed by blockade of the BTLA/CD160 pathways during vaccination.
Dawany N; Parzych EM; Showe LC; Ertl HC
Aging (Albany NY); 2016 Nov; 8(12):3272-3297. PubMed ID: 27922818
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of B and T lymphocyte attenuator and programmed death-1 on acceptance of partially versus fully MHC-mismatched cardiac allografts.
Tao R; Wang L; Han R; Wang T; Ye Q; Honjo T; Murphy TL; Murphy KM; Hancock WW
J Immunol; 2005 Nov; 175(9):5774-82. PubMed ID: 16237069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
